Revolution Medicines Stock (RVMD) Boosted By FDA Pancreatic Cancer Approval
Shares in oncology drugs group Revolution Medicines ($RVMD) were higher today after the U.S. Food and Drug Administration approved its treatment fo...
Revolution Medicines Inc. (RVMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 13,550,796 | $2,537,793,075 | -1% | 11.71% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 11,443,357 | $2,143,111,899 | +20% | 10.74% |
| 3. | Darwin Global Management Abhishek Trehan | 10,629,822 | $2,047,516,314 | +381% | 54.45% |
| 4. | Paradigm Biocapital Advisors Senai Asefaw | 6,361,323 | $1,191,348,571 | -5% | 22.31% |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,965,160 | $555,315,165 | +4% | 14.2% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $46.00 | 760,869 | $34,999,974.00 | 760,869 | 2024-12-05 | Filing | |
| $46.00 | 543,478 | $24,999,988.00 | 2,096,612 | 2024-12-05 | Filing | |
| $20.85 | 6,200 | $129,270.00 | 1,553,134 | 2023-03-10 | Filing | |
| $20.43 | 93,800 | $1,916,334.00 | 1,546,934 | 2023-03-10 | Filing | |
| $22.00 | 318,181 | $6,999,982.00 | 618,181 | 2023-03-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $212.06 | 3,314 | $702,761.21 | 55,907 | 2026-08-21 | Filing | |
| $211.34 | 4,500 | $951,037.65 | 59,221 | 2026-08-21 | Filing | |
| $210.26 | 2,540 | $534,072.34 | 63,721 | 2026-08-21 | Filing | |
| $209.25 | 25,817 | $5,402,199.50 | 66,261 | 2026-08-21 | Filing | |
| $208.37 | 17,323 | $3,609,572.72 | 92,078 | 2026-08-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,695,790 | $2,564,947,573 | 0.04% | |
| 2. | 12,200,422 | $2,284,894,993 | 0.1% | |
| 3. | 10,736,145 | $2,010,360,348 | 0.82% | |
| 4. | 9,088,661 | $1,702,124,432 | 0.04% | |
| 5. | 8,294,855 | $1,553,460,444 | 0.07% |
News See All
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal.
Can Revolution Medicines (RVMD) Turn A New Ally Into Global Reach?
Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia.
Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11...
10 Best Hot Stocks to Buy for June
The volatility in global markets is yet again in the spotlight, with stocks pulling back from all-time highs.
10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller
What sets billionaire Stanley Druckenmiller apart from other Wall Street giants is his frankness, humility, and openness to learn.
Truist Assumes Coverage of Revolution Medicines (RVMD), Lifts PT
Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best medical stocks to invest in according to billionaires. Truist assumed coverage of Revolution Medicines, Inc.
12 Best Medical Stocks to Invest In According to Billionaires
Talking about at what point bond yields create a meaningful risk to investors, she was of the view that if they get above the 5% range, then this “correction” or pullback will be justified.
Needham Keeps Buy Rating on Revolution Medicines (RVMD) Despite Wider Loss
Tom Steyer ranks among the list of the richest hedge fund managers in the world. Revolution Medicines, Inc.
16 Richest Hedge Fund Managers in the World
Fiscal year 2025, aided by an AI-powered stock market surge, proved to be a phenomenal year for hedge fund managers.
Hedge Fund Resource Center